Minrad eyes $32.5m target from 10 million share offering:
This article was originally published in Clinica
Executive Summary
Acute care medical device and pharmaceuticals developer Minrad International is floating 10 million shares, priced at $3.25 each, on the US Amex stock exchange where the company trades. Net proceeds raised from the public offering will go towards the expansion of the firm's Bethlehem, Pennsylvania facility, capital investment in its new headquarters in Orchard Park, New York, R&D efforts, debt repayment and general corporate purposes.